This prior work has greatly expanded our insight into the effects of SGLT-2 inhibitors in the myocardium, but it fails to account for how a modern high-fat diet and metabolic syndrome (MS) influence SGLT-2 inhibitor function in the myocardium. This evidence concerns the gene SLC5A2 and metabolic syndrome.